Compare DexCom, Inc. (DXCM) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kraft Heinz Co — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Kraft Heinz Co trades at $22.27 (market cap $26.66B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Kraft Heinz Co pays a 7.12% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Kraft Heinz Co for 129 Days on average.
| DXCM | KHC | |
|---|---|---|
Market Cap | $31.86B | $26.66B |
Volume | 3,607,070 | 31,300,109 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $27.62 |
52-Week Low | $54.84 | $21.21 |
Typical Hold Time | 62 Days | 129 Days |
Enterprise Value | $31.32B | $42.98B |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Kraft Heinz (KHC) trades at $22.48, up 2.27% today, but remains in a bearish technical trend. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though recent quarters have beaten EPS estimates. Operating cash flow remains strong at $4.46 billion, supporting a $0.40 dividend. News highlights focus on brand revitalization efforts, such as new Philadelphia cream cheese flavors, as part of a broader turnaround strategy.
The outlook is mixed: valuation metrics like P/B of 0.74 suggest potential undervaluation, but persistent net losses and high debt pose risks. Analyst sentiment is cautious with a consensus price target of $24.50. The stock's near-term direction hinges on successful execution of cost management and volume recovery initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
